Completed OBSERVATIONAL NCT05789771

Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. (ATLANT)

Abemaciclib Combined With Endocrine Therapy or as a Single Agent for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. Prospective, Multicentre, Non-interventional, Observational Study.

Sponsor: Blokhin's Russian Cancer Research Center

Conditions HR+/HER2- Breast Cancer Metastatic Disease Аdvanced Disease

Interventions Abemaciclib

Updated 4 times since 2023 Last updated: Mar 29, 2023 Started: Apr 1, 2022 Primary completion: Dec 1, 2022 Completion: Dec 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05789771, this observational or N/A phase trial focuses on HR+/HER2- Breast Cancer and Metastatic Disease and remains completed. Sponsored by Blokhin's Russian Cancer Research Center, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Apr 2023 — Jul 2024 [monthly]

Completed

First recorded

Apr 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Blokhin's Russian Cancer Research Center
Russian Society of Clinical Oncology

Data source: Blokhin's Russian Cancer Research Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia